XXXX expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in @entity95 and @entity19 .

@entity10056 @entity19 @entity95 @entity683 @entity1573 @entity56 @entity11230 @entity375
Currently available vaccines for the pandemic @entity683 (H1N1) 2009 produced in @entity1573 eggs have serious impediments viz limited availability, risk of @entity56 and the possible selection of sub-populations differing from the naturally occurring virus, whereas the cell culture derived vaccines are time consuming and may not meet the demands of rapid global vaccination required to combat the present/future pandemic. Hemagglutinin (HA) based subunit vaccine for H1N1 requires the HA protein in glycosylated form, which is impossible with the commonly used bacterial expression platform. Additionally, bacterial derived protein requires extensive purification and refolding steps for vaccine applications. For these reasons an alternative heterologous system for rapid, easy and economical production of @entity11230 protein in its glycosylated form is required. The HA gene of novel H1N1 A/California/04/2009 was engineered for expression in @entity10056 as a soluble secreted protein. The full length HA- synthetic gene having a-secretory tag was integrated into @entity10056 genome through homologous recombination. The resultant Pichia clones having multiple copy integrants of the transgene expressed full length HA protein in the culture supernatant. The Recombinant @entity375 derived H1N1 HA protein elicited neutralising antibodies both in @entity19 and @entity95 . The sera from immunised animals also exhibited Hemagglutination Inhibition (HI) activity. Considering the safety, reliability and also economic potential of Pichia expression platform, our preliminary data indicates the feasibility of using this system as an alternative for large-scale production of recombinant @entity683 HA protein in the face of @entity683 pandemic threat.
